Daria Lemann-Blumenthal Takes the Helm at NanoDrops as CEO

In a significant development for the med-tech landscape, NanoDrops, an innovative Israeli startup specializing in vision correction technology, has announced the appointment of Daria Lemann-Blumenthal as its new CEO. This strategic move comes as the company seeks to enhance its growth trajectory and further develop its groundbreaking technologies aimed at revolutionizing the field of eye care.

Daria Lemann-Blumenthal is no stranger to the ophthalmic industry. As the former co-founder and CEO of BELKIN Vision, she played a pivotal role in the development of Direct Selective Laser Trabeculoplasty (DSLT), a procedure designed to make glaucoma treatments more accessible and efficient. Under her leadership, BELKIN Vision achieved a remarkable milestone, culminating in its acquisition by Alcon Pharmaceuticals for approximately $466 million, a deal celebrated in the industry for its value and impact.

With over two decades of experience, Lemann-Blumenthal brings a wealth of knowledge and expertise to NanoDrops. She holds an LL.B. and an Executive MBA, blending legal and business acumen with her deep understanding of ophthalmology. Her appointment comes at a crucial time for NanoDrops, as the company prepares to embark on human clinical trials for its innovative vision correction technology which combines laser techniques with nanoparticles.

"At NanoDrops, we are pioneering a minimally invasive approach to vision correction for conditions such as presbyopia and myopia, aiming to give patients enhanced control over their visual acuity," said Lemann-Blumenthal. She expressed her excitement about joining the company, emphasizing the strong technological and medical foundation upon which NanoDrops stands. Her vision aligns with the company's goal to elevate its clinical studies and boost industry engagement.

Lemann-Blumenthal will be working closely with co-founder and Chief Medical Officer, Professor David Smadja. Smadja, who has a remarkable reputation in the ophthalmology field, heads the Innovation Committee of the International Society of Refractive Surgery and serves as an associate professor at Hadassah Medical Center in Jerusalem. Together, they form a formidable leadership team, combining technical expertise with business strategy.

In a statement regarding Lemann-Blumenthal's appointment, Smadja highlighted the essential need for business expertise as NanoDrops transitions into its next growth phase, which includes human clinical trials. He stated, "Daria possesses the precise expertise we need to navigate this pivotal stage. Her background in the ophthalmic industry and proven track record in business development will be invaluable as we aim to launch our revolutionary products into the market."

Assaf Barnea, Chairman of the Board and Managing Partner of Sanara Capital, voiced his confidence in Lemann-Blumenthal’s ability to lead the company. He remarked, "With Daria at the helm, NanoDrops stands to exemplify how bio-convergence practices can enhance patient care. Her leadership will undoubtedly push the boundaries of what we can achieve in this space."

Moreover, Assoc. Prof. Arthur Cummings, MD, who chairs NanoDrops' medical advisory board, welcomed Lemann-Blumenthal and acknowledged her stellar reputation for driving growth. Cummings noted that her previous success—and the foresight she brings to the company—positions NanoDrops for significant achievements and high-value outcomes in the future.

NanoDrops, founded in 2020, specializes in a unique corneal imprint procedure that utilizes a proprietary nanoparticle filling. This innovative approach ensures a minimally invasive and reversible process, allowing patients the flexibility to customize their vision correction solutions as their needs evolve. With Lemann-Blumenthal at the helm, the future for NanoDrops looks promising as it aims to transform the landscape of vision correction.

For more information on NanoDrops and its cutting-edge technology, visit www.nano-drops.com.